04-01-2021
Ophthalmic Sciences announces initiation of clinical trials of its novel intraocular pressure tracking technology for glaucoma treatment

Tel Aviv, January 4, 2020 – Ophthalmic Sciences, an eHealth Ventures eyecare company and the inventor of the IOPerfect™ intraocular pressure (IOP) tracking product, is pleased to announce the initiation of a pilot clinical trial at Assuta Ashdod Hospital in Israel, with the first patient set to be recruited in early January 2021.

Prof. Joseph Pikkel, MD, the principle investigator noted on this occasion: “obtaining frequent IOP measurements has long been a challenge in eye care, we are excited at the opportunity to take part in the study of this promising technology”.

The IOPerfect™ is the first image processing based, non-contact IOP measuring device. It is an ideal home-use telemedicine device and will be competitively priced to increase acceptance. The VR headset-like mobile product uses artificial intelligence (AI) algorithms to analyze captured video imaging and provides fast, user friendly and reliable IOP measuring, a key biomarker for monitoring and treating glaucoma.

Underlined by its advisory board member Robert Weinreb, MD, considered the world’s leading glaucoma expert, “a reliable and easy to use technology that would enable our patients to self-track their intraocular pressure, as proposed by Ophthalmic Sciences, would be a major step forward to more effectively diagnose and treat glaucoma”. Further technology platform applications such as early detection of cataract, corneal edema and exophthalmia are planned to be incorporated into a future all-inclusive eyecare diagnostics suite based on its proprietary aiMap™ AI-engine.

Having experienced a successful, accelerated development and feasibility phase, the Ophthalmic Sciences team has managed to bring forward a first-in-human ready product in a record 15 months from inception. A total of up to 200 patients will be recruited in the trial which will pave the way to initiation of a pivotal study later in 2021 – a critical milestone required towards product approval in the United States and Europe. With well over 70 million patients worldwide, 3 million in the US alone, glaucoma is a major chronic disease and the second leading cause of global adult blindness with a market valued at $7B. The Company plans to obtain FDA and CE approvals and be market ready in 2022.

The company is honored to celebrate this occasion with the establishment of its medical advisory board consisting of distinguished experts including Prof. Robert Weinreb, MD, who said “I am honored to join the Ophthalmic Sciences Advisory Board and look forward to working with them on their promising technology” as well as world renowned glaucoma specialist Prof. Murray Fingeret, O.D. who added “the need for telediagnostics based on home care is significant and constantly growing, with the Covid-19 crisis emphasizing this demand even more. We seek to improve our quality of care through technologies that enable patients to monitor their condition at home so that we can remotely monitor the disease and adjust the treatment regimen accordingly, a meaningful benefit for all involved. Just as blood pressure and glucose readings are selfadministered at home by patients, it is evident that the breakthrough technology Ophthalmic Sciences is presenting would finally enable better glaucoma care through reliable measurement of intraocular pressure in a cost-effective and user-friendly manner. With IOP being a key biomarker for glaucoma management, this would improve
the quality of care for patients. I am excited to take part in the company’s journey and
assist in bringing this vital solution to patients”.

The Company’s CEO, Mr. Ariel Weinstein said “this fantastic group achievement comes two months ahead of schedule and is a meaningful value creator placing us on a far more comfortable position to enter the post-seed financing we now begin working on. The pace of development here, actively supported by the eHealth Ventures team and partners, has exceeded my expectations. Profs. Weinreb and Fingeret’s agreement to take part in our advisory board is a further vote of confidence in the company, its technology and its product’s market need”.

About Ophthalmic Sciences:
Ophthalmic Sciences, a privately owned company established in 2019, is dedicated to harnessing AI-based image processing technology to address unmet needs in eyecare with a particular focus on tele-diagnosis. Based on technology developed by its founders Noam Hadas, a veteran entrepreneur and Gabriel Dan, the company vision is to become a leader in this field. Ophthalmic Sciences operates within eHealth Ventures, a prominent digital health venture fund and incubator.
For more information contact ariel@op-sci.com

About eHealth Ventures:
eHealth Ventures is the leading early-stage Digital Health investor (VC and Incubator) in Israel and a partnership of multinational medical organizations, industry leaders and financial investors including Maccabi – Israel’s leading HMO, Amgen, Medison Ventures, SCI and others. eHV has invested in 14 innovative ventures to date.
For more information contact ophir@ehv.health

 

 

 

 

Underlined by its advisory board member Robert Weinreb, MD, considered the world’s leading glaucoma expert, “a reliable and easy to use technology that would enable our patients to self-track their intraocular pressure, as proposed by Ophthalmic Sciences, would be a major step forward to more effectively diagnose and treat glaucoma”. Further technology platform applications such as early detection of cataract, corneal edema and exophthalmia are planned to be incorporated into a future all-inclusive eyecare diagnostics suite based on its proprietary aiMap™ AI-engine.

NEWS
We move fast and push our companies to move faster.
Timing is everything - we get it.
For all news items
eHealth Ventures by Numbers:
15
Portfolio Companies
1300
Companies Reviewed
 
 
115
Years of experience for 4 principles
 
7
X
Fair Value Appreciation on Portfolio
Partners & Collaborators